Related Experiment Video
Updated: Apr 29, 2026
Minimal Erythema Dose MED Testing
Published on: May 28, 2013
Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease
Eli L Diamond1, Lorenzo Dagna2, David M Hyman3
1Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY;
Insights
Erdheim-Chester disease (ECD) is a rare clonal disorder. This study presents the first multidisciplinary consensus guidelines for managing ECD, offering recommendations for assessment and treatment.
Area of Science:
- Rare diseases
- Histiocytosis
- Genetics
Background:
- Erdheim-Chester disease (ECD) is a rare non-Langerhans histiocytosis.
- ECD is increasingly diagnosed and involves multiple organ systems.
- BRAFV600E mutations are found in over 50% of patients, suggesting a clonal disorder with inflammation as a key factor.
Purpose of the Study:
- To establish the first multidisciplinary consensus guidelines for the clinical management of Erdheim-Chester disease.
- To provide standardized recommendations for assessment and treatment based on current evidence and expert opinion.
Main Methods:
- A consensus-based approach was developed at the First International Medical Symposium for ECD.
- Recommendations were formulated by international experts in ECD pathophysiology and therapy.
- A critical appraisal of existing literature and clinical experience informed the guidelines.
Main Results:
- Detailed recommendations for initial clinical, laboratory, and radiographic assessment of ECD patients.
- Evidence-based treatment recommendations for Erdheim-Chester disease management.
- Formalized consensus guidelines to aid clinical practice and future research.
Conclusions:
- The developed guidelines provide a standardized framework for ECD management.
- These consensus recommendations aim to improve patient care and facilitate research in Erdheim-Chester disease.
Abstract:
Erdheim-Chester disease (ECD) is a rare, non-Langerhans histiocytosis. Recent findings suggest that ECD is a clonal disorder, marked by recurrent BRAFV600E mutations in >50% of patients, in which chronic uncontrolled inflammation is an important mediator of disease pathogenesis. Although ∼500 to 550 cases have been described in the literature to date, increased physician awareness has driven a dramatic increase in ECD diagnoses over the last decade. ECD frequently involves multiple organ systems and has historically lacked effective therapies. Given the protean clinical manifestations and the lack of a consensus-derived approach for the management of ECD, we provide here the first multidisciplinary consensus guidelines for the clinical management of ECD. These recommendations were outlined at the First International Medical Symposium for ECD, comprised of a comprehensive group of international academicians with expertise in the pathophysiology and therapy of ECD. Detailed recommendations on the initial clinical, laboratory, and radiographic assessment of ECD patients are presented in addition to treatment recommendations based on critical appraisal of the literature and clinical experience. These formalized consensus descriptions will hopefully facilitate ongoing and future research efforts in this disorder.
Related Concept Videos
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
01:29Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
01:21Rheumatic Heart Disease III: Medical Management
01:20Rheumatic Heart Disease IV: Nursing Management
01:21Barrett Esophagus-II: Clinical Manifestations and Management
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
01:26Nephrotic Syndrome II : Assessment and Medical Management